Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2013

View Archived Issues

Phase III study of GSK-2132231A in melanoma misses first co-primary endpoint

Novartis enters into global licensing and research collaboration with Regenerex

Novartis presents new series of USP2 inhibitors

New mouse model mimics hyperargininemia

Novel TYK2 inhibitors divulged by Takeda Pharmaceuticals

iPierian secures financing to launch spin-out company

Panax ginseng extract prevents adverse cisplatin effects in vivo

New locked nucleic acid antisense oligonucleotides disclosed by U.S. team

Blood smear filipin staining speeds NP-C diagnosis

Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety

Novel tricyclic IAP antagonists synthesized at Takeda

FDA accepts corifollitropin alfa NDA for review

Merck KGaA divulges novel protein kinase inhibitors

Oncolytics Biotech reports final tumor response data for phase II study of Reolysin

Bayer Intellectual Property patents new FGFR inhibitors

Neuren Pharmaceuticals cleared to conduct phase II NNZ-2566 trial

Debiopharm and TCG Lifesciences to develop a novel class of antibiotics

Spanish team prepares novel sigma1 receptor ligands

Chimerix begins phase III trial of brincidofovir

BL-8040 receives FDA orphan drug designation for treatment of AML

Gamida Cell reports transplantation of first patient in phase I/II study of NiCord in blood cancers

Aegerion obtains orphan drug designation in Japan for use of lomitapide in treatment of HoFH

Stem Cell Therapeutics to initiate IND-enabling program for CD47 antagonist

FDA grants orphan status to ublituximab for two non-Hodgkin's lymphoma subtypes

Neurocrine discloses results from phase IIb trial of NBI-98854 for treatment of tardive dyskinesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Heartbeam wins appeal, gains FDA clearance
BioWorld MedTech
Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...